RIBOMIC Inc. is engaged in the drug discovery business based on the platform Ribomic Aptamer Refined Therapeutics System related to aptamer drug discovery technology. Its drug discovery business is divided into self discovery and co-discovery divisions. Self Drug Discovery division develops aptamer and licenses and out the results to pharmaceutical companies. The Co-Discovery division earns the research expenses paid by the alliance partner for the shared part of co-discovery business with alliance pharmaceutical companies researching aptamer pharmaceutical.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
11/06/26	62.00 ¥	0.00%	303,100
10/06/26	62.00 ¥	0.00%	676,600
09/06/26	62.00 ¥	-4.62%	551,600
08/06/26	65.00 ¥	-1.52%	231,100
05/06/26	66.00 ¥	+1.54%	821,600

Delayed Quote Japan Exchange

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - Japan Exchange Other stock markets 09:30:00 11/06/2026 +03			5-day change	1st Jan Change
62.00 ^JPY	0.00%		-7.46%	-20.51%

03-19	Ribomic Files IND For Phase III Trial Of Achondroplasia Drug In Japan	MT
03-19	Ribomic Inc Announces IND Application for Phase III Clinical Trial of Umedaptanib Pegol for Achondroplasia Treatment	CI

Market Cap	4.78B 29.78M 25.84M 23.82M 22.32M 41.7M 2.85B 42.57M 284M 110M 1.37B 112M 109M	P/E Ratio 2024	-3.24x	P/E Ratio 2025	-3.89x
Enterprise Value	1.74B 10.86M 9.42M 8.68M 8.14M 15.2M 1.04B 15.52M 104M 40.11M 501M 40.75M 39.87M	EV / Sales 2024	-	EV / Sales 2025	666x
Free-Float	96.31%	Yield 2024 *	-	Yield 2025	-

03-19	Ribomic Files IND For Phase III Trial Of Achondroplasia Drug In Japan	MT
03-19	Ribomic Inc Announces IND Application for Phase III Clinical Trial of Umedaptanib Pegol for Achondroplasia Treatment	CI
03-10	Ribomic Reports Positive Phase II Results For Achondroplasia Drug	MT
03-10	Ribomic, Inc. Announces Summary Report on Primary Endpoint for Phase Ii Clinical Trial of Umedaptanib Pegol in the Treatment of Achondroplasia	CI
02-12	Ribomic Inc. Reports Earnings Results for the Nine Months Ended December 31, 2025	CI
01-14	Ribomic Files Patent for Anti-Autotaxin Aptamer RBM-006	MT
01-14	RIBOMIC, Inc. Announces New Substance Patent Application for Highly Active RBM-006 (Anti-Autotaxin Aptamer) and its Drug Impact in a Mouse Model of Diabetic Retinopathy	CI
11-21	Ribomic Shows Sustained Two-Year Gains in Achondroplasia Trial	MT
07/10/25	Ribomic Reports Positive Phase 2 Results for Achondroplasia Drug Umedaptanib Pegol	MT
07/10/25	Ribomic, Inc. Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of Up to +5.0 Cm/Year with Biweekly Administration in Children Aged 5 Years and Older	CI
07/10/25	Ribomic announces positive phase 2 cohort 2 results for umedaptanib pegol in achondroplasia	RE
25/09/25	Ribibo, Inc. Announces Discovery of Therapeutic Effects of Umedaptanib Pegol in A Diabetic Retinopathy Model and New Patent Application for Use	CI
20/08/25	Ribomic Reports Sustained Efficacy of Achondroplasia Drug in Long-Term Trial	MT

07/10/25	RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to +5.0 cm/year with Biweekly Administration in Children Aged 5 Years and Older	BU
05/11/24	RIBOMIC Announces Positive Interim Results from Phase IIa Trial of umedaptanib pegol in Achondroplasia Demonstrating Increase in Annualized Growth Rate of up to +4.6 cm/year in Children 5 Years of Age and Older in the Low Dose Cohort	BU
03/08/24	RIBOMIC Announces Completion of Patient Enrollment in Early Phase II Study of umedaptanib pegol for Achondroplasia and Initiation of Dosing in Cohort 2 of Early Phase II Clinical Study	BU
05/12/23	RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)	BU
29/07/22	RIBOMIC : Announces Issuance of US Patent for its RBM-010, Novel Drug Candidate for Osteoarthritis	PU

Ribomic Inc. Stock

Stocks

4591

JP3974850004

Biotechnology & Medical Research

Valuation: Ribomic Inc.

Chart: Ribomic Inc.

Latest news : Ribomic Inc.

Press Releases: Ribomic Inc.

News in other languages: Ribomic Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Ribomic Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

08/10/25	RIBOMIC veröffentlicht positive Ergebnisse der Phase-2-Kohorte 2 für Umedaptanib Pegol bei Achondroplasie, die eine Steigerung der annualisierten Wachstumsrate um bis zu +5,0 cm/Jahr bei zweiwöchentlicher Verabreichung bei Kindern ab 5 Jahren zeigen
06/11/24	RIBOMIC gibt positive Zwischenergebnisse der Phase-IIa-Studie mit Umedaptanib Pegol bei Achondroplasie bekannt, die eine Steigerung der annualisierten Wachstumsrate von bis zu +4,6 cm/Jahr bei Kindern ab 5 Jahren in der niedrig dosierten...
20/02/20	RIBOMIC : kündigt erste Injektion in der klinischen Phase-2-Studie von RBM-007 (TOFU-Studie) bei Patienten mit feuchter altersbedingter Makula-Degeneration an
19/06/19	RIBOMIC : gibt positive Topline-Ergebnisse der klinischen Phase-1/2a-Studie an RBM-007 (SUSHI-Studie) bei Patienten mit feuchter altersbedingter Makuladegeneration bekannt

1 week	-7.46%
Current month	-11.43%
1 month	-23.46%
3 months	-38.00%
6 months	-19.48%
Current year	-20.51%

Manager	Title	Age	Since
Yoshikazu Nakamura PSD	President	78	01/04/2012
Toshiya Imai DFI	Director of Finance/CFO	-	-
Takeo Adachi CTO	Chief Tech/Sci/R&D Officer	38	01/10/2023

Director	Title	Age	Since
Yoshikazu Nakamura BRD	Director/Board Member	78	01/10/2005
Toshiaki Nishihata BRD	Director/Board Member	77	01/06/2016
Hisato Oiwa BRD	Director/Board Member	68	01/06/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RIBOMIC INC.	0.00%	-7.46%	-32.61%	-61.25%	21.27M
ARGENX SE	+1.65%	+6.42%	+53.16%	+109.62%	54.82B
WUXI APPTEC CO., LTD.	+0.03%	-1.80%	+49.57%	+43.94%	43.27B
BIONTECH SE	+2.44%	-0.99%	-15.89%	-19.21%	21.79B
INSMED INCORPORATED	+4.77%	-7.68%	-1.14%	+396.72%	19.92B
WUXI BIOLOGICS (CAYMAN) INC.	+0.81%	-8.38%	+12.77%	-33.24%	15.67B
GENMAB A/S	+0.53%	+2.08%	+8.89%	-40.13%	15.26B
EXELIXIS, INC.	+1.23%	+1.50%	+28.59%	+179.07%	13.22B
PHARMAESSENTIA CORPORATION	-5.27%	+3.89%	+90.88%	+208.02%	11.58B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.74%	-1.05%	+12.88%	-	11.94B
Average	+0.45%	-1.27%	+20.71%	+87.06%	20.75B
Weighted average by Cap.	+0.95%	+1.16%	+31.85%	+97.34%

	2024	2025
Net sales	-	2M 12.46K 10.81K 9.97K 9.34K 17.45K 1.19M 17.82K 119K 46.04K 575K 46.78K 45.78K
Net income	-1.02B -6.38M -5.54M -5.1M -4.78M -8.94M -611M -9.12M -60.89M -23.57M -295M -23.95M -23.44M	-1.02B -6.34M -5.5M -5.07M -4.75M -8.88M -607M -9.07M -60.53M -23.44M -293M -23.81M -23.3M
Net Debt	-3.4B -21.18M -18.38M -16.94M -15.88M -29.66M -2.03B -30.28M -202M -78.25M -978M -79.51M -77.8M	-3.04B -18.92M -16.42M -15.14M -14.18M -26.5M -1.81B -27.05M -181M -69.91M -873M -71.04M -69.51M

1 week	60	67
1 month	60	80
Current year	60	120
1 year	60	141
3 years	60	170
5 years	60	944
10 years	60	1,109